Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24076247 | 0.93 | PRMT5 (0.49) | PARP1ALDH1A1SMN1; SMN2ARPRMT5 | |
| SCHEMBL27384831 | 0.85 | PARP1 (0.43) | PARP1ALDH1A1SMN1; SMN2ARPOLB | |
| SCHEMBL27384835 | 0.85 | PARP1 (0.47) | PARP1ALDH1A1SMN1; SMN2ARPOLB | |
| SCHEMBL10147195 | 0.83 | PARP1 (0.48) | PARP1ALDH1A1SMN1; SMN2ARPOLB | |
| SCHEMBL29480940 | 0.82 | PRMT5 (0.59) | PARP1ALDH1A1SMN1; SMN2ARPOLB | |
| SCHEMBL17825064 | 0.82 | PRMT5 (0.59) | PARP1ALDH1A1SMN1; SMN2ARPOLB | |
| SCHEMBL21575781 | 0.81 | PRMT5 (0.49) | PARP1ALDH1A1SMN1; SMN2ARPRMT5 | |
| SCHEMBL4117496 | 0.80 | GAA (0.51) | SMN1; SMN2ARPRMT5WDR77TSHR | |
| SCHEMBL30231202 | 0.79 | PRMT5 (0.68) | PARP1ALDH1A1SMN1; SMN2ARPOLB | |
| SCHEMBL7462930 | 0.79 | PRMT5 (0.68) | PARP1ALDH1A1SMN1; SMN2ARPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | PARP1 514/4885ALDH1A1 1934/4885SMN1; SMN2 4576/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | PARP1 499/4885ALDH1A1 2376/4885SMN1; SMN2 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.